Detalhe da pesquisa
1.
Second-Line Switch to Dolutegravir for Treatment of HIV Infection.
N Engl J Med
; 388(25): 2349-2359, 2023 Jun 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-37342923
2.
HIV pre-exposure prophylaxis services, provision, and delivery in the European treatment network of HIV, hepatitis and global emerging infectious diseases (NEAT ID).
HIV Med
; 25(3): 353-360, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38040445
3.
Stability in care and risk of loss to follow-up among clients receiving community health worker-led differentiated HIV care: Results from a prospective cohort study in northern Tanzania.
Trop Med Int Health
; 29(4): 309-318, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38279832
4.
Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized Trial.
Clin Infect Dis
; 76(5): 861-870, 2023 03 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36259527
5.
Incidence of Hypertension and Blood Pressure Changes in Persons With Human Immunodeficiency Virus at High Risk for Cardiovascular Disease Switching From Boosted Protease Inhibitors to Dolutegravir: A Post-hoc Analysis of the 96-week Randomised NEAT-022 Trial.
Clin Infect Dis
; 77(7): 991-1009, 2023 Oct 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37207617
6.
Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir.
J Antimicrob Chemother
; 78(9): 2361-2365, 2023 09 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37539492
7.
Influence of UGT1A1 and SLC22A6 polymorphisms on the population pharmacokinetics and pharmacodynamics of raltegravir in HIV-infected adults: a NEAT001/ANRS143 sub-study.
Pharmacogenomics J
; 23(1): 14-20, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36266537
8.
Effectiveness of provider-initiated versus client-initiated HIV testing by different health facility departments in Northern Tanzania.
AIDS Res Ther
; 20(1): 44, 2023 07 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37420276
9.
Call to action: how can the US Ending the HIV Epidemic initiative succeed?
Lancet
; 397(10279): 1151-1156, 2021 03 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-33617770
10.
Atherogenicity of low-density lipoproteins after switching from a protease inhibitor to dolutegravir: a substudy of the NEAT022 study.
J Antimicrob Chemother
; 77(7): 1980-1988, 2022 06 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-35411401
11.
Factors associated with overweight/obesity in a cohort of people living with HIV over 50 years of age.
AIDS Care
; 34(4): 542-544, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34082628
12.
Beyond viral suppression: Quality of life among stable ART clients in a differentiated service delivery intervention in Tanzania.
Qual Life Res
; 31(1): 159-170, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34052956
13.
Human Immunodeficiency Virus (HIV) Care Models During the Coronavirus Disease 2019 (COVID-19) Era.
Clin Infect Dis
; 73(5): e1222-e1227, 2021 09 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34492689
14.
Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV.
J Antimicrob Chemother
; 76(9): 2380-2393, 2021 08 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34120186
15.
Analysis of Pharmacovigilance Databases for Dolutegravir Safety in Pregnancy.
Clin Infect Dis
; 70(12): 2599-2606, 2020 06 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31595301
16.
Five-year follow-up of patients enrolled in the NEAT 001/ANRS 143 randomized clinical trial: NEAT 001/ANRS 143 LONG TERM study.
J Antimicrob Chemother
; 75(6): 1618-1622, 2020 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32211883
17.
Switching from boosted PIs to dolutegravir in HIV-infected patients with high cardiovascular risk: 48 week effects on subclinical cardiovascular disease.
J Antimicrob Chemother
; 75(11): 3334-3343, 2020 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32737482
18.
Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial.
J Antimicrob Chemother
; 75(3): 628-639, 2020 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31754703
19.
Determining the Origins of Human Immunodeficiency Virus Type 1 Drug-resistant Minority Variants in People Who Are Recently Infected Using Phylogenetic Reconstruction.
Clin Infect Dis
; 69(7): 1136-1143, 2019 09 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-30534981
20.
Immediate Versus Deferred Switching From a Boosted Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 Study.
Clin Infect Dis
; 68(4): 597-606, 2019 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29912307